Yves Humblet

25.9k citations
174 papers · 15.9k · 7 hit papers · h-index 41

Impact in

  • Oncology top 0.05%
    • Colorectal Cancer Treatments and Studies
    • Cancer Treatment and Pharmacology
    • Pancreatic and Hepatic Oncology Research
  • Hepatology top 0.2%
    • Hepatocellular Carcinoma Treatment and Prognosis

Papers in

    • Colorectal Cancer Treatments and Studies 88
    • Cancer Treatment and Pharmacology 42
    • Lung Cancer Research Studies 29
    • Pancreatic and Hepatic Oncology Research 14
    • Lung Cancer Treatments and Mutations 41
    • Gastric Cancer Management and Outcomes 20

Yves Humblet

174 papers receiving 15.5k citations

Yves Humblet's Hit Papers

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial 2012 · 2.1k citations
2.1k0+7+14Years since publication10002.0k3.0k

Peers

Yves Humblet
Comparison fields: 5 of 134
  • Oncology 13.0k
  • Hepatology 2.8k
  • Pulmonary and Respiratory Medicine 5.6k
  • Cancer Research 2.4k
  • Pathology and Forensic Medicine 2.8k
Replace Christophe Louvet with:
Christophe Louvet France
David R. Spigel United States
Takayuki Yoshino Japan
Antoine Adenis France
Joon Oh Park South Korea
Gabriella Fontanini Italy
Lee S. Rosen United States
Sabine Tejpar Belgium
William Novotny United States
Johanna C. Bendell United States
Yves Humblet relative to Christophe Louvet France Christophe Louvet's profile →
Citations per field
00.5×1.5×
Christophe Louvet · 1×
Citations per year

Countries citing papers authored by Yves Humblet

Since Specialization
Citations

This map shows the geographic impact of Yves Humblet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yves Humblet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yves Humblet more than expected).

Fields of papers citing papers by Yves Humblet

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yves Humblet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yves Humblet. The network helps show where Yves Humblet may publish in the future.

Co-authors

The 25 scholars most cited alongside Yves Humblet, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Yves Humblet Line = papers co-authored together Yves Humblet links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 174 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
Hit paper breakdown →
20043874
2
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Hit paper breakdown →
20122053
3
Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer
Hit paper breakdown →
20071516
4
Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
Hit paper breakdown →
20101351
5
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab
Hit paper breakdown →
2007660
6
Phase III Trial of Gemcitabine Plus Tipifarnib Compared With Gemcitabine Plus Placebo in Advanced Pancreatic Cancer
Hit paper breakdown →
2004616
7
Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer
Hit paper breakdown →
2009504
8 2018278
9 2009276
10 2007260
11 2015228
12 2004194
13 2013185
14 2006178
15 1987159
16 2013145
17 2002136
18 2008129
19 2006129
20 2007128

About Yves Humblet

Yves Humblet is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Surgery, Cancer Research and Molecular Biology, having authored 174 papers that have together received 15.9k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (88 papers), Cancer Treatment and Pharmacology (42 papers), Lung Cancer Treatments and Mutations (41 papers), Lung Cancer Research Studies (29 papers), Cancer Genomics and Diagnostics (22 papers), Gastric Cancer Management and Outcomes (20 papers), Colorectal and Anal Carcinomas (17 papers) and Pancreatic and Hepatic Oncology Research (14 papers). The work is most often cited by research in Oncology (13.0k citations), Hepatology (2.8k citations), Pulmonary and Respiratory Medicine (5.6k citations), Cancer Research (2.4k citations) and Pathology and Forensic Medicine (2.8k citations). Yves Humblet has collaborated with scholars based in Belgium, France and Italy. Frequent co-authors include Eric Van Cutsem, Salvatore Siena, Chris Verslype, David Cunningham, Armando Santoro, A. Harstrick, M. Mueser, Harry Bleiberg, Ian Chau and David Khayat. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, European Journal of Cancer, Lung Cancer and British Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact